piracetam has been researched along with Amyotrophic Lateral Sclerosis in 1 studies
Piracetam: A compound suggested to be both a nootropic and a neuroprotective agent.
Amyotrophic Lateral Sclerosis: A degenerative disorder affecting upper MOTOR NEURONS in the brain and lower motor neurons in the brain stem and SPINAL CORD. Disease onset is usually after the age of 50 and the process is usually fatal within 3 to 6 years. Clinical manifestations include progressive weakness, atrophy, FASCICULATION, hyperreflexia, DYSARTHRIA, dysphagia, and eventual paralysis of respiratory function. Pathologic features include the replacement of motor neurons with fibrous ASTROCYTES and atrophy of anterior SPINAL NERVE ROOTS and corticospinal tracts. (From Adams et al., Principles of Neurology, 6th ed, pp1089-94)
| Excerpt | Relevance | Reference |
|---|---|---|
| " focuses on the current clinical development of the antiepileptic drug levetiracetam for amyotrophic lateral sclerosis." | 7.73 | Clinical development of levetiracetam for amyotrophic lateral sclerosis. ( Davies, SL; Moral, MA, 2006) |
| " focuses on the current clinical development of the antiepileptic drug levetiracetam for amyotrophic lateral sclerosis." | 3.73 | Clinical development of levetiracetam for amyotrophic lateral sclerosis. ( Davies, SL; Moral, MA, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Davies, SL | 1 |
| Moral, MA | 1 |
1 other study available for piracetam and Amyotrophic Lateral Sclerosis
| Article | Year |
|---|---|
Clinical development of levetiracetam for amyotrophic lateral sclerosis.
Topics: Amyotrophic Lateral Sclerosis; Animals; Anticonvulsants; Clinical Trials as Topic; Humans; Levetirac | 2006 |